Nanobiotix Appoints Arnd Christ as New CFO Amid Late-Stage Trials
Nanobiotix (NASDAQ: NANO) appointed Arnd Christ as CFO, succeeding a five-year incumbent. The move coincides with pivotal Phase III data readouts for NBTXR3 in the U.S. and EU. Nanobiotix is a France-based biotech with U.S. listing and cross-border R&D operations.
51CFO view：For Nasdaq-listed biotechs, CFO succession triggers SEC scrutiny on continuity of MD&A disclosure practices and timely 8-K filing for material developments (e.g., FDA designations). The new CFO must demonstrate hands-on experience with U.S. quarterly reporting cycles and clinical trial milestone accounting.
Nanobiotix (NASDAQ: NANO) appointed Arnd Christ as CFO, succeeding a five-year incumbent. The move coincides with pivotal Phase III data readouts for NBTXR3 in the U.S. and EU. Nanobiotix is a France-based biotech with U.S. listing and cross-border R&D operations.
Source：Google News · CFO 任命
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
How is a US-listed CFO paid?
Base, equity incentive and listing-milestone bonus: structure and ranges.
Read →
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →